Dr. Onyema Ogbuagu, Nigerian-born, Yale Principal Investigator on the Pfizer-BioNTech phase 3 vaccine trial, is one of the doctors at the heart of the Covid-19 vaccine breakthrough.
An Infectious Disease Specialist and a Virologist by training, he obtained his Doctor of Medicine (M.D.) degree from the University of Calabar, Cross River State, Nigeria, in 2003; completed a Yale Medicine Infectious Diseases Fellowship and joined the Faculty of the Yale School of Medicine, United States in 2012.
Dr. Ogbuagu is deeply involved in clinical work in Africa and for over 6 years has been a faculty of the Human Resources for Health program in Rwanda where he mentored medical residents on infectious diseases-related problems particularly HIV/AIDS and antimicrobial resistance.
He is also a faculty of the HIV training track of the Yale-Internal Medicine primary care program and the Director of the HIV Clinical Trials program at the Yale AIDS Program, Section of Infectious Diseases at the Yale School of Medicine.
Having mostly focused on HIV medicine in the field of treatment and prevention, in the course of his career, he was well equipped and had the machinery ready to conduct clinical trials when Covid-19 hit.
Dr.OnyemaOgbuagu is today, celebrated for his lead role in the Pfizer-BioNTech vaccine trial, the first out of eleven vaccine candidates in late-stage trials to announce that its vaccine is 95% effective in preventing Covid-19 infections. He is one of the twin sons of Prof.ChibuzoOgbuagu, a former Vice Chancellor of Abia State University, Uturu, and Prof. Stella Ogbuagu, a Professor of Sociology.